- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Mary Lou Smith on Bringing Better Cancer Care to the Community
The National Comprehensive Cancer Network Guidelines bring the practices of cancer care thought leaders out to the community, said Mary Lou Smith, JD, MBA, co-founder of the Research Advocacy Network.
The National Comprehensive Cancer Network Guidelines bring the practices of cancer care thought leaders out to the community, said Mary Lou Smith, JD, MBA, co-founder of the Research Advocacy Network.
She shared her own experience of being diagnosed with breast cancer. Because she worked in healthcare, Ms Smith knew to get a second opinion, which gave her the option of having a lumpectomy instead of a mastectomy.
“I was given a different option than I would have been given out in the community,” she said. “And that mad me angry, actually, because I didn’t feel that was fair to other women.”
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
